• Loading stock data…

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

[#item_full_content]

Print Friendly, PDF & Email
Spread the word